Kornimate/medical-research-clean huggingface dataset:
ultrasonographic subcutaneous scar scoring system for traumatic hand injured patients

Conditions: Hand Injuries

Summary: this study aims to develop an objective scar scoring system via ultrasonography and try to apply it to clinical using. this study was divided into two parts. the first part of the study is an observational study design. the scar scoring system will be developed, and its test-retest reliability and criterion-related validity will be tested in this part. the second part is also an observational study design. the clinical application of the system on traumatic injured patients is conducted in the second part. the results from this scar scoring system are correlated with hand function measurements. moreover, every scar will be recorded three times within one month during routine rehabilitation to investigate the change.


Eligibility criteria:
inclusion criteria: * above 20 years old * traumatic hand injury (distal from wrist joint above 8 weeks and within one year) * able to do active motion and resistive activities * understand and cooperate the experiment exclusion criteria: * injured by burn * have impairment in peripheral nerve and affect the movement * combined with other central nerve deficits

Keywords: traumatic hand injury ultrasonography subcutaneous scar
kidney ai-enabled care transformation

Conditions: Chronic Kidney Diseases

Summary: in the kidney action study, ckd (chronic kidney disease) patients at increased risk of progression to esrd (end stage renal disease) will be randomly assigned to either standard of care in a specialist nephrology outpatient clinic or to receiving ckd care supported by a novel ai-supported (artificial intelligence) software solution.

the advancing american kidney health (aakh) initiative has the goal of an ambitious 25% reduction of esrd incidence by 2030. there is a lack of successful integrated care programs to reach this goal. the ckd population is very heterogeneous, this explains the different risk of progression to esrd in different patients. however, guidelines (gls) for the treatment of ckd patients address risk factors identified in the ckd population at large. thus, all ckd patients at the same stage receive similar treatments no matter the specific risk of developing esrd. up to 5.9% of europeans have ckd stages 3-5. treating this huge number of patients would strain health systems from both the organizational and economical point of view. it is reasonable to think that dedicating a personalized management specifically to ckd patients at high risk of progression would be cost-effective. gls include behavioral (e.g. lifestyle, nutrition) as well as medical (e.g. drug therapy) interventions. although patient's engagement and empowerment play a pivotal role in successful disease treatment, there is lack of evidence on practices to foster them in ckd patients. kidney action is a program that supports nephrologists in predicting disease progression for ckd patients and developing multidisciplinary, personalized, evidence-based treatment and care plans. patient engagement and empowerment is a fundamental part of the program.

Eligibility criteria:
inclusion criteria: * male or female aged ≥18 years at the time of signing the informed consent * chronic kidney disease with egfr \ 300 mg/g creatinine (egfr=estimated glomerular filtration rate; uacr=urine albumin-to-creatinine ratio) * patient is willing to comply with the study requirements for therapy during the entire study period * patient is capable of providing written informed consent to participate in the study exclusion criteria: * patients with underlying renal disease likely to receive disease-specific therapy other than soc (standard of care) * patient expected to require renal replacement therapy within less than one year from study inclusion

Keywords: chronic kidney disease end stage kidney disease artificial intelligence patient engagement progression
board games among mild cognitive impairment patients experience (game project)

Conditions: Cognitive Impairment, Mild

Summary: nowadays, on geriatric centres, cognitive decline used to be prevented by pen and paper exercises (calero garcía \& navarro gonzalez, 2006). however, as lampit et al. (2014) suggest, studies based on the efficacy and effectiveness of new cognitive-based interventions in order to improve these cognitive processes are fundamental (lampit et al., 2014). cognitive-based interventions are interventions that directly or indirectly try to improve cognitive processes (chiu et al., 2017). between the different kinds of cognitive-based interventions, cognitive training permits stablish randomized controlled trials. cognitive training consists of repeating during a concrete time a standardized set of tasks in order to maintain or improve one or some cognitive processes. meta-analysis studies have shown that computerized cognitive training can improve in a moderate size some cognitive processes in elderly people with mild cognitive impairment or dementia (hill et al., 2017) and without those diagnoses (lampit, hallock, \& valenzuela, 2014; chiu et al., 2017). although it seems that computerized training is effective, safe and secure, it is important to note the social component of the definition of health (oms, 1948). chang, wray \& lin (2014) found that social relationships predict the use of leisure activities and this predict a better physical health and wellbeing psychological. in fact, a comparative study found that those elderly people that have played board games have a 15% lower risk of having dementia diagnose and problems related with memory (dartigues et al., 2013). to sum up, the aim of this research project is to test the effectiveness of a cognitive training based on modern board and card games in elderly people with a diagnose of mild-cognitive impairment in comparison to do cognitive paper and pencil tasks or in a wait-list comparison group.


Eligibility criteria:
inclusion criteria: * participation in cognitive disease center * amnestic mci diagnoses (clinical diagnoses following the guidelines of petersen et al. 2011) * global deterioration scale (gds) 2-3 values * participation assessing outcomes of the caregivers in the study exclusion criteria: * participation in another cognitive training program * dementia, neurologic or other disease non-neurodegenerative, which could affect cognitive change over time (medical-reported) * severe visual impairment, language impairment or motoric impairment of the upper extremity which significantly affects ability to solve jigsaw puzzles (medical-reported)

Keywords: memory executive functions cognitive training cognitive enrichment modern board and card games
clinical performance of stenfilcon a versus filcon ii 3

Conditions: Myopia

Summary: clinical performance of stenfilcon vs. filcon ii 3

the objective of this study is to compare the comfort and clinical performance of stenfilcon vs. filcon ii 3 compared to subject's habitual contact lenses. the null hypothesis is that there is no difference in the clinical performance between the two sets of lenses.

Eligibility criteria:
inclusion criteria: subjects must satisfy the following conditions prior to inclusion in the study: * based on his/her knowledge, must be in good general health. be of legal age (18 years) or older. * be able and willing to adhere to the instructions set forth in this protocol and complete all specified evaluation. * read, indicate understanding of, and sign written informed consent (appendix 1) * require a contact lens prescription between -0.50 and -6.00 and have no more than -.75dioptor (d) of astigmatism in both eyes * achieve visual acuity of 6/9 or better in each eye with a spherical contact lens prescription. * an existing soft contact lens wearer of any modality. * must be able to wear their lenses at least 6 full days over the 7 days; 14 hours per day, assuming there are no contraindications for doing so. * have normal eyes with no evidence of abnormality or disease. for the purposes of this study a normal eye is defined as one having: * no amblyopia. * no evidence of lid abnormality or infection (e.g. entropion, ectropion, chalazia, recurrent styes). * no clinically significant slit lamp findings (e.g. infiltrates or other slit lamp findings greater than grade 2: corneal edema, tarsal abnormalities, and conjunctival injection). * no other active ocular disease (e.g. glaucoma, history of recurrent corneal erosions, cornea \[infiltrates\], conjunctiva, lids, and intraocular infection or inflammation of an allergic, bacterial, or viral etiology.) * no aphakia exclusion criteria: any of the following will render a subject ineligible for inclusion: * neophytes, who have not worn lenses before * greater than 0.75d of refractive astigmatism in either eye * presence of clinically significant (grade 3 or above) anterior segment abnormalities; inflammations such as iritis; or any infection of the eye, lids, or associated structures. * presence of ocular or systemic disease or need of medication which might interfere with contact lens wear. * slit lamp findings that would contraindicate contact lens wear such as: * pathological dry eye or associated findings * pterygium, pinguecula or corneal scars within the visual axis * neovascularization \> 0.75 mm in from the limbus * giant papillary conjunctivitis (gpc) grade 3 or above * anterior uveitis or iritis (past or present) * seborrheic eczema, seborrheic conjunctivitis * history of corneal ulcer or fungal infections * poor personal hygiene * a known history of corneal hypoesthesia (reduced corneal sensitivity). * contact lens best corrected snellen visual acuities (va) worse than 6/9 * aphakia, keratoconus or a highly irregular cornea
the benefit in terms of improvement in haemoglobin level at 6 months in premature babies receiving alternate iron substitution 4 times a week compared to a daily substitution

Conditions: Premature Birth

Summary: bienfer is a double-blinded randomized controlled trial about iron substitution and abdominal pain. premature babies and low birth weight babies have lower iron stores than term newborns and are therefore at greater risk of iron deficiency and anemia. iron deficiency could have consequences for cerebral development. ferric substitution reduces the risk of iron deficiency and anemia. it is common to replace premature babies with iron substitution between 2 weeks and 6 months of life. in practice, the medical staff notice that newborn with iron substitution have abdominal pain and constipation. a study in the adult population shows that alternate iron supplementation versus daily supplementation improved iron absorption, with no difference in hemoglobin level and decrease abdominal pain. studies in children shows that intermittent iron supplementation do not change hemoglobin and ferritin level and improve adherence. there is no data comparing daily versus alternate supplementation in premature babies. the aim of the study is to evaluate if alternate (4 times/week) iron supplementation is equivalent to daily iron substitution for hemoglobin values in premature babies between 28 0/7 weeks amenorrhea (wa) and 34 6/7 wa, and if it reduces abdominal discomfort and inflammation, and if it improves compliance.


Eligibility criteria:
inclusion criteria: * premature babies between 28 0/7wa and 34 6/7 wa * parental consent, postnatal * age of 2 weeks exclusion criteria: * anemia \< 80g/l at 2 weeks of age * intraventricular hemorrhage stage iii and iv * necrotizing enterocolitis * enteral feeding less than 100ml/kg/j after 2 weeks of life * congenital disorder
detection of choroidal nevus cells in vitrectomy fluid

Conditions: Nevus

Summary: the purpose of this study is to determine if the investigators can detect the presence of choroidal nevi cells in the vitreous fluid of humans, as this may improve the diagnosis and classification of choroidal nevi and melanomas in the future.

approximately 7% of the population has a choroidal nevus, or "freckle," in the back of the eye. like a nevus on the skin, there is potential for malignant change to a melanoma. dermatologists have the ability to quickly and easily biopsy suspicious skin lesions while ophthalmologists currently have no way of determining the malignant potential of choroidal nevi other than a fine needle aspiration (which is invasive and has the potential complications of bleeding and retinal detachment). this study's sole aim is to see if choroidal nevi cells are present in the inside fluid of the eye. the investigators plan to analyze the fluid of the eye, which is routinely removed during retina surgery, to detect any nevus cells. if the investigators are able to detect these cells, then future studies may allow us to better classify choroidal nevi for potential malignant change.

Eligibility criteria:
inclusion criteria: * patients with a choroidal nevus who are undergoing routine vitrectomy surgery for another indication (such as epiretinal membrane or macular hole repair). exclusion criteria: * patients without a choroidal nevus * children under the age of 18 * pregnant and nursing females

Keywords: choroidal nevus vitrectomy
safety and immunogenicity of flublok quadrivalent vs iiv4 in adults 18-49 years of age

Conditions: Influenza

Summary: randomized, double-blind trial of safety and immunogenicity of flublok quadrivalent versus inactivated influenza vaccine (iiv4) in 1350 healthy, medically stable adults 18-49 years of age. serum samples for hemagglutinin inhibition titers will be determined pre- and 28 days post-vaccination. subjects will be followed for 6 months after vaccination for serious and/or medically-attended adverse events.

as the spectrum of influenza vaccines rapidly evolves to quadrivalent formulations with the intention of offering broader protection to include both lineages of influenza b strains, it is appropriate to transition flublok from a trivalent to a quadrivalent formulation. the demonstration of non-inferior post-vaccination hemagglutination inhibition assay (hai) geometric mean titers (gmts) to antigens in the flublok quadrivalent formulation compared to those of the matching antigens in a us - approved iiv4 is intended to support licensure of flublok quadrivalent for the adult population for which flublok trivalent is currently approved. the comparison of safety and reactogenicity of flublok quadrivalent to that of iiv4 is expected to confirm a similar safety profile.

Eligibility criteria:
inclusion criteria: * ambulatory, in good health or medically stable * able to understand and comply with planned study procedures * provide written informed consent * negative urine pregnancy test within 24 hours prior to vaccination (women of child-bearing potential) exclusion criteria: * prior serious or severe reaction to influenza vaccine * known contraindication to either study vaccine * receipt of any other influenza vaccine within 180 days prior to enrollment * plan to receive another licensed influenza or other vaccine during the duration of this study * receipt of any significant new diagnosis, medication (licensed or investigational), or licensed vaccine within 30 days prior to enrollment in this study * underlying disease or therapeutic intervention that might adversely affect the immune response * plans to participate in any investigation involving an investigational product during this study. * pregnant, lactating or planning to become pregnant within 30 days of study vaccine. * any clinical or social circumstance that in the opinion of the investigator could interfere with compliance with study procedures or interfere with the interpretation
the effect of amiloride and spironolactone in healthy persons

Conditions: High Blood Pressure

Summary: this study will investigate whether retaining potassium in the body will lead to changes in blood pressure and changes in blood and urine samples.

the purpose is to measure the effect of amiloride and spironolactone on: 1. renal function (gfr, u-aqp2, u-enacβ, u-camp, u-pge2, ch20, fena, fek), 2. pulsbewave velocity, augmentation index and central blood pressure, 3. vasoactive hormones (prc, angii, aldo, avp, anp, bnp and endot), and 4. ambulatory blood pressure

Eligibility criteria:
inclusion criteria: * healthy * non-smokers exclusion criteria: * smoking * under medical treatment
a study of eribulin-based regimen versus other chemotherpy in triple-negative metastatic breast cancer (eri-based-01).

Conditions: Breast Cancer

Summary: a single-center retrospective study about efficacy and safety of eribulin-based regimen in the treatment of metastatic triple-negative breast cancer and comparison with other chemotherapy regimen

not provided

Eligibility criteria:
inclusion criteria: 1. women aged 18-70. 2. the pathologic diagnosis of unresectable recurrent or metastatic triple-negative breast cancer ［er-negative(ihc\<1%), pr-negative(ihc\<1%), her2-negative（ihc-/+ or ihc++ and fish/cish-）］. 3. eastern cooperative oncology group (ecog) performance status of ≤ 2. 4. patients with at least one measuring lesion that was conformed to recist v1.1 standard. 5. patients receiving eribulin-based therapy received at least two cycles of eribulin-based chemotherapy. eribulin was treated until disease progression, unacceptable toxicity or patient refusal of treatment. 6. adverse events were recorded according to the national cancer institute common terminology criteria for adverse events (nci-ctcae 5.0). exclusion criteria: 1. patients previously treated with eribulin. 2. patients with grade ≥3 adverse events did not recover according to ctcae 5.0 criteria. 3. not applicable to combined chemotherapy, or allergic or intolerant to related drugs.
evaluation of facial growth in two primary protocols used in the surgical treatment of unilateral cleft lip and palate patients

Conditions: Unilateral Cleft Lip and Palate; Cleft Lip; Cleft Palate; Developmental Disabilities; Restricted Language Development

Summary: the purpose of this study is to evaluate which surgical protocol for treating unilateral cleft lip and palate (uclp), a single or two stage repair ( with hard palate late closure) will have less impact in mid facial growth. the study hypothesis states that a two stage cleft palate repair , with a late hard palate repair will reduce maxillary growth impairment.

the study is being conducted at cadefi- centro de atenção aos defeitos da face do imip (craniofacial center) in imip-instituto de medicina integral professor fernando figueira-, recife pe- pernambuco-, brazil. all children were and will be operated by the same plastic surgeon in the operating room in imip. the sample size was calculated in 64 patients, 32 to gi ( one stage repair) and 32 to gii ( two stage repair, with a hard palate late closure), considering taking a statistical power of 90% with a 5% significance, determined with a difference of at least 25% between the two groups. note : this sample was calculated for the dependent variable commonly present in patients with unilateral lip and palate cleft : atresia of the dental arches. the groups are numbered in post op care attendance of the lip repair, according to randomization sequence done in computerized statistical program. the randomization is being held after the first month of the lip repair surgery. the surgeon, and parents or guardians (who have already signed the informed consent form) will not have prior access to information on the type of allocation in each group. subsequently it will be added in patients chart the record set for the patient group. \>study variables independent variables:. group i (palate closure in two surgical times and gii (closure of the palate in a surgical time) also will be considered independent variables age, sex, birth weight and maternal education. dependent variables: the presence of postoperative infection, initial and intermediate cleft sizes, dimensional changes of the transverse arch, the evaluation indexes of dental arch relationship(goslom,atack yardsticks) and speech outcomes evaluation grades

Eligibility criteria:
inclusion criteria: * patients with unilateral cleft lip and palate admitted consecutively in cadefi-imip between august 1, 2011 and july 31, 2015 exclusion criteria: * patients with associated syndromes that retard the neuro-psycho-motor and speech development; * patients without clinical conditions for performing the surgical chronology protocol; * patients whose parents or guardians who are not in accordance with the informed consent statement proposed by the researcher

Keywords: operative procedures
smart after-care in patients with prostate cancer

Conditions: Prostate Cancer

Summary: this study aims to examine whether smart after-care service (internet-and mobile-based lifestyle intervention) has an effect on patients' satisfaction and clinical outcomes in patients with prostate cancer on androgen deprivation therapy. patients with prostate cancer on androgen deprivation therapy will participate in the study. the study design is a randomized controlled trial. the patients were randomly assigned to intervention or usual care groups. intervention patients received smart after-care service for 3 months. primary endpoint was an increase in patients' physical function as assessed using 2 minute walking test. secondary endpoints included improvement in muscle strength, short physical performance battery, body composition, and health-related quality of life.

after-care is a process targeted towards restoration or maintenance of the physical, mental, intellectual and social abilities of an individual affected by cancer. internet-and mobile-based lifestyle intervention have emerged as potential modalities to complement and increase accessibility to after-care. in order to meet the growing need for after-care services, we developed a smart after-care system that will assess the efficacy of a web-based smartphone-enabled intervention. the system provided specialized tools on after-care of prostate cancer including information on nutrition, physical activity, medication adherence, and mobile device that can connect to the smartphone. patients with prostate cancer on androgen deprivation therapy will be screened for having adequate musculoskeletal and cardiopulmonary function.the study design is a randomized controlled trial. the patients were randomly assigned to intervention or usual care groups. intervention patients received smart after-care management for 3 months. primary endpoint was an increase in patients' physical function as assessed using 2 minute walking test. secondary endpoints included improvement in muscle strength, short physical performance battery, body composition, and health-related quality of life.

Eligibility criteria:
inclusion criteria: * males diagnosed with prostate cancer * current treatment with adt (gnrh agonist/antagonist with or without antiandrogen) for a minimum of 6 months after randomization * having android smartphone exclusion criteria: * having another (active) malignant disease within 3 month before randomization * having severe cardiopulmonary disease * having bone pain due to bone metastasis, (or) pathologic fracture * receiving total knee replacement arthroplasty, (or) total hip replacement arthroplasty * no permission from treating/study physician to participate in exercise